Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature

Background: Despite multidisciplinary treatment approaches, the prognosis for patients with high-grade glioma (HGG) is poor, with a median overall survival (OS) of 14.6 months for glioblastoma multiforme (GB). As high levels of vascular endothelial growth factor A (VEGF) are found in HGG, targeted a...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Jennifer Jeck, Rebecca Kassubek, Jan Coburger, Simone Edenhofer, Stefan S. Schönsteiner, Albert C. Ludolph, Bernd Schmitz, Jens Engelke, Regine Mayer-Steinacker, Jan Lewerenz, Lars Bullinger
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: SAGE Publishing 2018-01-01
Loạt:Therapeutic Advances in Neurological Disorders
Truy cập trực tuyến:https://doi.org/10.1177/1756285617753597

Internet

https://doi.org/10.1177/1756285617753597

Những quyển sách tương tự